Combination Therapy for Age-Related Macular Degeneration.

Exclusion Criteria

• •1. Individuals with choroidal neovascularization from causes other than AMD.
• •2. Individuals physically unable to tolerate intravenous fluorescein angiography or Verteporfin injections. (Specifically, individuals with inadequate venous access or an allergy/sensitivity to fluorescein dye/porphyrins will be excluded.)
• •3. Any intraocular surgery within 3 months in the study eye.
• •4. Prior retinal or vitreous surgery including posterior segment vitrectomy or scleral buckling in the study eye.
• •5. Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome.
• •6. Individuals with physical or mental disabilities that prevent accurate vision testing.
• •7. History of treatment of CNV in study eye other than extrafoveal confluent laser photocoagulation.
• •8. Prior photodynamic therapy for CNV in the study eye.
• •9. Active hepatitis or clinically significant liver disease
• •10. Any patient with recent history of new onset cardiac disease or thromboembolic CNS event in the past.
• •11. Subjects who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks.
• •12. Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections.
• •13. Women of child-bearing potential who are not on two forms of effective contraception during the trial and for at least 60 days following the last dose of study medications.